Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
SWOG Cancer Research Network
Checkpoint Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Calithera Biosciences, Inc
SCRI Development Innovations, LLC
Spectrum Pharmaceuticals, Inc
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Stanford University
Boehringer Ingelheim
Wales Cancer Trials Unit
National Cancer Institute (NCI)